#### **PCT**

(30) Priority Data:

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



#### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:
A61F 2/28

A1
(11) International Publication Number: WO 00/15152
(43) International Publication Date: 23 March 2000 (23.03.00)

(21) International Application Number: PCT/EP99/06682

(22) International Filing Date: 10 September 1999 (10.09.99)

09/152,437 14 September 1998 (14.09.98) US

(71) Applicant: BIONX IMPLANTS OY [FI/FI]; Hermiankatu 6-8L, FIN-33720 Tampere (FI).

(72) Inventors: TÖRMÄLÄ, Pertti; Saarenkarjenkuja 5 As. 2, FIN-33720 Tampere (FI). KELLOMAKI, Minna; Kasvitarhankatu 8, FIN-33500 Tampere (FI). WARIS, Timo; Gunillankuja 2 B 16, FIN-00870 Helsinki (FI).

(74) Agent: KEIL & SCHAAFHAUSEN; Cronstettenstrasse 66, D-60322 Frankfurt am Main (DE).


(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

#### **Published**

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: A BIOABSORBABLE, LAYERED COMPOSITE MATERIAL FOR GUIDED BONE TISSUE REGENERATION



#### (57) Abstract

This invention describes a rigid layered composite material (1) comprising a bioabsorbable plate layer (2) and a bioabsorbable web layer (3) for guided bone tissue regeneration, particularly suited for use in the treatment of cranial bone defects (7).

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AΤ	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	$\mathbf{U}\mathbf{Z}$	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	$\mathbf{z}\mathbf{w}$	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		



# A BIOABSORBABLE, LAYERED COMPOSITE MATERIAL FOR GUIDED BONE TISSUE REGENERATION

#### 5 BACKGROUND OF THE INVENTION

10

15

20

25

The present invention describes a bioabsorbable layered surgical implant comprising two components. One component is a solid plate of bioabsorbable polymer and the other is a web made of bioabsorbable fibers. These implants guide and enhance bone healing and protect the soft tissues beneath the healing bone. These implants are particularly useful in cranioplasty.

Guided bone regeneration by means of implants has a long history, especially in cranioplasty, where there exists a great need to prevent damage to the brain by covering holes and other defects in cranial bone. The materials used to effect guided bone regeneration, such as would occur in cranioplasty, must meet several criteria. They must have, for example, good biocompatibility and high mechanical strength. Further, they should not cause bone erosion.

In the past, bone tissue grafts have been made, for example, as allografts from canine bone, human bone, decalcified bone, pericranium, and as autografts from the tibia, rib and crista iliac. See Zeiss Index and History of Plastic Surgery 900 BC- 1863 AD Baltimore, Williams & Wilkins, 1977, vol 1, pp 51-52; Chase S.W., Herndon C.H., The fate of autogenous and homogenous bone grafts: A historical review, Journal of Bone Joint Surgery 37 A, 1955, pp. 809-841; Prolo D.J., Cranial defects and cranioplasty, in Wilkins RH, Rengachary SS (eds): Neurosurgery, New York, McGraw-Hill, 1984, pp 1647-1656; Grant F.C., Norcross N.C., Repair of Cranial Defects By Cranioplasty, Annual Surgery vol. 110, 1939, pp. 488-512; Reeves D.L., Cranioplasty, Springfield IL, Charles C. Thomas, 1950; and Woolf J.I., Walker A.E., Cranioplasty, Collective review, International Abstracts Surgery 81,

1945, pp. 1-23, the entire disclosures of each of which are incorporated herein by way of this reference. However, there are problems associated with the use of bone tissue grafts. If the patient's own bone is used as a graft, a surgeon must perform an additional, traumatic operation to take the bone sample. If the bone graft is taken from another person or animal bone is used, viral contaminations or immunological problems are possible, even if the graft is treated to make it compatible with the patient's tissue.

5

10

15

20

Additionally, man-made biostable materials have been studied in cranioplasty applications, such as cellulose fibers, aluminum, gold, titanium, stainless steel, poly methyl methacrylate (PMMA), polyethylene and silicone. See, Habal M.B., Leake D.L., Maniscako J.E., A new method for reconstruction of major defects in the cranial vault, Surgery Neurology 6, 1976, pp. 137-138; Karvounis P.C., Chiu J., Sabin H., The use of prefabricated polyethylene plate for cranioplasty, Journal of Trauma 10, 1970, pp. 249-254; and Black S.P.W., Reconstruction of the supraorbital ridge using aluminum, Surgery Neurology 9, 1978, pp. 121-128, the entire disclosures of each of which are incorporated herein by way of this reference. However, the clinical use of most of these materials has been rejected due to severe tissue reactions. Further, biostable implants are particularly ill-suited for cranioplasty in children because a biostable implant prevents the immature skull bone from growing to adult size and, therefore, the implant needs to be removed in a second surgical procedure.

Many of the problems of biostable materials can be solved with implants made of bioabsorbable polymers, which cause fewer inflammatory reactions. The bioabsorbable implants are also suitable for children, because these implants resorb totally and the degradation products disappear from the body via metabolic routes. Moreover, these materials can be chosen to degrade quickly enough so that the growth of the child's cranium

is not restricted, thereby obviating the need for a second operation. Even with bioabsorbable plates, however, there is a desire to effect quicker bone regeneration and healing.

#### BRIEF SUMMARY OF THE INVENTION

5

10

15

20

Thus, it is a goal of the present invention to provide an implant, particularly for cranioplasty, that is bioabsorbable, yet strong enough to protect soft tissue, such as the brain, during the healing period.

It is further a goal of the present invention to provide an implant, particularly for cranioplasty, that may be easily shaped or formed and applied over a defect in a bone, such as the cranium.

It is further a goal of the present invention to provide an implant, particularly for cranioplasty, that will promote quick bone regeneration, thereby shortening the healing period.

It is further a goal of the present invention to provide an implant, particularly for cranioplasty, that will degrade quickly enough so as not to restrict the natural growth in children of the bone under repair.

These and other goals are met with the present invention, comprising a rigid and tough, yet easily shaped, layered bioabsorbable implant for guided bone tissue regeneration, which may be used as a bioabsorbable surgical cranioplasty implant. The implant described in more detail in this application comprises two components. One component is a solid plate of a bioabsorbable polymer and the other is a web, typically made of bioabsorbable fibers.

These implants have a surface structure that promotes bone growth on one side and prevents

tissue irritation on the other. Thus, implants of the present invention enhance bone healing and protect the soft tissues beneath the healing bone and around the implant.

## BRIEF DESCRIPTION OF THE DRAWINGS

5

10

15

20

The present invention will be more fully described in conjunction with the accompanying diagram wherein:

Figure 1 is a cross-sectional schematic view of one embodiment of the implant of the present invention covering a cranial defect.

#### DETAILED DESCRIPTION OF THE INVENTION

This invention relates to a bioabsorbable bone growth guiding implant, such as a cranioplasty implant, that adheres to bone, enhances growth and healing of the bone, and protects soft tissues, such as the brain, beneath the implant. The implant is manufactured by totally or partially joining together: (a) a solid and stiff bioabsorbable plate; and (b) a flexible and porous bioabsorbable web. These components are referred to herein as the (a) plate and (b) web layers. Both layers can be made of a bioabsorbable homopolymer, bioabsorbable copolymer, bioabsorbable polymer blend or polymer-based composite. These layers can be made of either the same or different materials, depending upon the particular application at hand. Possible biodegradable polymers to be used for the implant of the present invention are listed, *e.g.*, in WO 96/41596, the entire disclosure of which is incorporated herein by way of this reference.

With reference to Figure 1, which demonstrates an embodiment of the present invention, the implant can be implanted over the defect 7 in a bone 4, such as the cranium, to

protect the tissues 6 inside or below the defect 7, such as those inside the skull, from being damaged. The implant 1 comprises two layers, the rigid plate layer 2 and the web layer 3.

The plate layer 2 determines the shape and size of the implant and has enough strength and stiffness to act as a protective shield for the tissue 6. It may be specially cut and shaped to easily and closely cover the defect 7 and the surrounding bone 4. In a preferred embodiment of the present invention, the top side of the plate layer 2 is smooth to avoid the irritation of surrounding tissues which could cause an adverse reaction in the patient.

5

10

15

20

The plate layer 2 may be made from any of the prior art biodegradable materials using techniques known in plastics technology, including extrusion, injection molding and/or solid state deformation, or pressing to the desired shape with or without heat. It is also possible to mechanically machine the plate layer to the desired shape. It is also possible to use a combination of techniques, for example, using machining to form a curved implant from an extruded sheet.

The thickness of the plate layer 2 will generally range from about 0.05 mm to about 3 mm, preferably from about 0.2 mm to about 1.5 mm. It is preferable to make the plate layer 2 as thin as possible, while still retaining enough rigidity to adequately protect the soft tissue 6. The thickness and other dimensions of the plate layer 2 (and implant 1) will depend on the size of the defect 7 to be covered, as well as the curvature of the surrounding bone 4 and, therefore, can vary greatly.

The web layer 3 is located below the plate layer 2 and above the bone 4 and the defect 7. It has been found, surprisingly, that the web layer 3 directs and enhances bone growth by providing a porous surface along which and into which the bone tissue can grow and spread. The web layer 3 is therefore located on the side of the implant that is placed against the bone

4 and the defect 7. The sizes of the pores in the web structure are controlled so as to favor bone growth.

The favorable pore size for promoting bone growth along the fibrous web layer 3 of the present invention has been discovered to be between about  $30\mu m$  and about  $1000~\mu m$ . Typically, bone cells are not able to easily grow into pores smaller than about  $30~\mu m$ . With pore sizes larger than about  $1000~\mu m$ , bone growth is slower because there is less physical structure to which the bone cells can adhere themselves during regeneration. Most preferably, the pore size is between about  $50~\mu m$  and about  $400~\mu m$ , which best promotes bone growth.

10

5

In order to maintain the porosity of the web layer during the manufacturing of the implant 1, in a preferred embodiment of the present invention, the plate layer 2 and the web layer 3 are only partially or loosely attached to each other. This leaves a high degree of porosity in the surface structure of the web layer 3, which promotes rapid bone regeneration. The upper surface of the web layer 3 should be in contact with the plate layer 2, but not totally merged with the surface of the plate layer 2, thus leaving the web layer 3 porous.

15

The porous structure of the web layer can be manufactured from biodegradable fibers using any known methods from mechanical textile and plastics technology. The thickness of the fibers can vary from about 1  $\mu$ m to about 200  $\mu$ m. In a preferred embodiment of the invention, the fiber thickness is between about 5 $\mu$ m and about 150 $\mu$ m.

20

Structures suitable for the web component of this implant can be, for example, a cloth, a narrow fabric, a knit, a weave, a braid, or a web. In any case, the structure should be porous with pore size from about 30  $\mu$ m to about 1000  $\mu$ m, preferably between about 50  $\mu$ m to about 400  $\mu$ m. The web component can be manufactured using one type of fiber, for example

polyglycolide or polylactide fibers. It is also possible to make the web using two or more different types of fibers depending upon the particular application and desired physical characteristics of the implant.

5

10

15

20

In a preferred embodiment of the present invention, the web layer 3 is made of biodegradable polymer that degrades faster than the polymer used for the plate layer 2. Thus, the web layer 3 degrades before the plate layer 2, allowing the bone to develop a more dense structure and attach to the surface of the plate before the plate disintegrates. The plate component remains and gives the desired strength, shape, and protection to the defect, while the regenerating bone increases its strength and density. Simultaneously, but as a slower process, bone may also cover the other side of the implant by growing on top of it, starting from the edges of the plate. Regardless, the implant finally resorbs, having been replaced with new bone and/or connective tissue. Resorption products disappear from the body via metabolic routes. In the end, the bone defect is covered or filled in by the patient's own regenerated bone.

The implant 1 can be fixed to the bone 4 with various attachment techniques known in the art, such as bioabsorbable sutures, bioabsorbable tacks, minitacks or microtacks, or bioabsorbable screws, depending on the implantation site and size of the implant. In Figure 1, the implant 1 is attached to the bone 4 with small bioabsorbable screws 5.

The layers of the implant 1 may be joined to each other, *e.g.*, by welding, as is described in a patent application to Paasimaa S., Kellomäki M., and Törmälä P., entitled "A bioabsorbable 2-dimensional multi-layer composite device and its manufacturing method," which is being filed concurrently herewith, or they can be glued, hot-pressed, ultrasonically welded or welded with some other technique. The layers of the implant 1 may remain

separated before implantation, and joined during surgery by stitching them simultaneously to cover the cranial defect. They can also be joined together by attaching them to the bone using biodegradable tacks, minitacks, microtacks or miniscrews. These methods can also be used to attach the implant 1 with other prejoined components.

5

The implant 1 may contain various additives and modifiers that improve the processability of polymer, such as plasticizers and antioxidants. The components of the implant can also contain one or more bioactive, bone growth stimulating, or pharmaceutically active agents, like antibiotics, growth hormones or anticoagulants. Also, any bioceramic or bioactive glass (e.g., in the form of powder, flakes or fibers), which has been found to enhance bone healing, can be used as an additive. Typical examples of such bioceramics and bioactive glasses useful in this invention: hydroxyapatite, tricalcium phosphate and other calcium phosphates, Bioglass® (available from Research Center, University of Florida, Gainsville, Fla., USA), Ceravital®, Alumina, Zirconia, Bioactive gel-glass and other bioactive glasses.

15

10

According to a particularly advantageous embodiment of the present invention, the web layer is embedded with gel or paste containing bone growth factor(s), like NOVOS (made by and available from Stryker Biotech, Natic, MA, USA), which comprises osteoconductive type I bone collagen and osteogenic protein 1. These growth factors induce and further stimulate the bone growth under the cranioplasty, thereby intensifying bone formation and healing.

20

After the description above of the present invention and certain specific embodiments thereof, it will be readily apparent to those skilled in the art that many variations and modifications may be made to the present invention without departing from the spirit and

scope thereof. The following non-limiting examples further demonstrate various embodiments of the present invention.

#### Example 1.

5

10

15

20

The repair of a  $10 \times 10$  mm defect in the skull of adult New Zealand rabbits was carried out using each of the following five methods (A. through E.) to compare the rate of bone regeneration for each of those methods.

- A. The soft tissues were closed over the defect.
- B. A polylactide sheet of thickness 0.4 mm was prepared by extrusion of poly-D,L-lactide (D/L ratio 96/4), and a piece of size 15 x 15 mm was cut out from it, the corners rounded off and the plate bent to the desired convex form. The plate was fixed over the defect with DEXON stitches (available from Davis & Geck, USA) extending into the surrounding periosteum and the soft tissues were closed over it.
  - C. A piece of 0.15 mm thick polyglycolide membrane having a fibrous surface (Biofix®, available from and manufactured by Bionx Implants Ltd., Tampere, Finland) was cut to the shape of the plate described in method B, above, and placed over the defect with its fiber side towards the bone and defect. The plate described in method B, above, was placed on top of the defect and the membrane. The membrane and the plate were fixed in position with DEXON stitches extending into the surrounding periosteum and the soft tissues closed over them.
  - D. A piece of fiber web composed of polyglycolide fibers and bioactive glass fibers (composition of Na<sub>2</sub>O, 6 mol. %;  $K_2O$ , 7.9 mol. %; MgO, 7.7 mol. %; CaO, 22.1 mol. %;  $P_2O_5$ , 1.7 mol. %; and  $SiO_2$ , 54.6 mol. %) was cut to the shape of the plate as described in

method C above, and placed over the defect with a plate (as described in method B, above) on top of it. The plate and the web were fixed in position with DEXON stitches extending into the surrounding periosteum and the soft tissues were closed over the plate.

5

10

15

20

E. 50 μg recombinant growth factor (rTGF-β1, recombinant transgenic growth factor, available from and delivered by Helsinki University, Dept. Of Orthopedics and Traumatology) was mechanically mixed into a sterile 85/15 (wt. %/wt. %) blend consisting, respectively, of oligo L-lactate and copolymer of ε-caprolactone and D,L-lactide (60/40 in D/L). The paste was painted onto the fibrous surface of a membrane as described in method C, above, and the membrane was then placed in position with the surface containing growth factor and polymer blend carrier towards the bone (and the defect). A plate of the kind described in method B, above, was placed on top of it, the membrane and the plate were fixed in position with DEXON stitches extending into the surrounding periosteum, and the tissues were closed over the plate.

Each procedure was performed in triplicate, and the animals were sacrificed after 12 weeks in all cases.

There occurred no bone growth in series A. In the case of series B, bone growth had proceeded to 40 percent of the defect area, but the defect was still partly filled with connective tissue in the center. Series C, D and E, which used implants according to the present invention, however, showed complete coverage of the defect by bone, although this was about 50 percent thinner in the center than at the edges in series C and 40 percent thinner in that respect in series D. In the series E, the new bone was only 30 percent thinner in the center of the defect than at the edges. Thus, with the implants of the present invention, it is

possible to greatly increase the rate of cranial bone regeneration previously achieved with prior art biodegradable implants.

#### Example 2.

5

10

15

20

The repair of a  $10 \times 10$  mm defect in the skull of adult New Zealand rabbits was carried out using the following 2 methods, to compare the rate of bone regeneration for those methods.

- A. A stiff plate was prepared by extrusion of poly(ortho ester) (a rigid copolymer of diketene acetal and 60:40 molar ratio of rigid and flexible diols manufactured as described in: Heller J., Poly(ortho esters), Advances in Polymer Science 107: 41-92, 1993, the entire disclosure of which is incorporated herein by way of this reference) to a thickness of 0.5 mm, and cut into pieces of size 15 x 15 mm. The corners of the plate were rounded off and the pieces bent to the desired convex form under heat. As shown in Figure 1, the plate was fixed to the bone surrounding the defect using poly(ortho ester) mini-studs and the soft tissues were closed over the plate.
- B. The inner surface of the plate described above in method A was moistened with a solvent, which made the surface of the plate tacky, and broken poly(ortho ester) fibers were sprinkled onto it so that they adhered to it and made the surface uneven and porous.

Each series (A and B) comprised 12 animals, of which 4 were sacrificed after 3 weeks, 4 after 24 weeks and 4 after 48 weeks. No soft tissue inflammatory reactions were seen in either series at the end of the experiment. No new bone tissue was observed in series A after three weeks, but 10 percent of the area of the defect had been covered by new bone in series B. After 24 weeks a coverage of 90 percent had been achieved in series A and full

coverage in series B, while after 48 weeks the underside of the implant had become fully ossified in both series and some bone had been formed on the upper surface. As shown in Fig. 1, the plate was fixed to the bone surrounding the defect using poly (ortho ester) (the same copolymer as described above in method A) mini-studs.

#### We claim:

15

An at least partially bioabsorbable cranial implant comprising:
 a rigid plate layer of bioabsorbable material having upper and lower sides,
 a fibrous web layer of bioabsorbable material in at least partial contact with the lower
 side of the rigid plate layer.

- 2. The implant of claim 1 wherein the rigid plate layer comprises bioabsorbable homopolymer, copolymer, polymer blend, or polymer composite.
- The implant of claim 1 wherein the fibrous web layer comprises bioabsorbable homopolymer, copolymer, polymer blend, or polymer composite.
  - 4. The implant of claim 1 wherein the rigid plate layer and the fibrous web layer are made of the same material.
  - 5. The implant of claim 1 wherein the material of the fibrous web layer bioabsorbs faster than the material of the rigid plate layer.
- The implant of claim 1 wherein the fibrous web layer contains pores that are between
   30μm and 1000 μm in diameter.
  - The implant of claim 6 wherein the fibrous web layer contains pores that are between
     μm and 400 μm in diameter.

8. The implant of claim 1 wherein the implant further comprises bioceramic glass.

=

9. The implant of claim 1 wherein the implant further comprises a bioactive agent.

5 10. A method for performing cranioplasty comprising the step of:
at least partially attaching the implant of claim 1 to a defect in a cranium so that the
fibrous web layer abuts the cranium.




FIG.1

Int. tional Application No
PCT/EP 99/06682

A. CLASS	IFICATION OF	SUBJECT	MATTER
IPC 7	A61F2/	′28	

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC  $\,\,7\,$  A61F

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

C. DOCUMENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
X	WO 92 10218 A (GORE & ASS) 25 June 1992 (1992-06-25) figure 1 page 5, line 18 -page 8, line 4 page 9, line 19 -page 10, line 2 claims 1,3-11,16	1-5,9	
Υ		6,7	
Y	WO 98 07384 A (MACROPORE INC) 26 February 1998 (1998-02-26) figures 2,5 page 17, line 5 - line 34 page 20, line 25 -page 22, line 16 page 25, line 10 - line 27 claim 1	6,7	

χ Further documents are listed in the continuation of box C.	χ Patent family members are listed in annex.
<ul> <li>Special categories of cited documents:</li> <li>"A" document defining the general state of the art which is not considered to be of particular relevance</li> <li>"E" earlier document but published on or after the international filing date</li> <li>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</li> <li>"O" document referring to an oral disclosure, use, exhibition or other means</li> <li>"P" document published prior to the international filing date but later than the priority date claimed</li> </ul>	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "&" document member of the same patent family
Date of the actual completion of the international search  3 February 2000	Date of mailing of the international search report $10/02/2000$
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL – 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo ni,  Fax: (+31-70) 340-3016	Authorized officer  Mary, C

1

Inte ional Application No
PCT/EP 99/06682

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	 
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 186 448 A (BREKKE JOHN H) 5 February 1980 (1980-02-05) figures 8-12 column 7, line 32 -column 8, line 9	1-4,9
1	claim 8	8
<b>(</b>	WO 95 28900 A (KIRSCH AXEL) 2 November 1995 (1995-11-02) figures 1-5 page 8, line 36 -page 11, line 4 claim 1	8
	US 5 380 328 A (MORGAN FRANK H) 10 January 1995 (1995-01-10) figures 1-8 column 6, line 4 - line 58	1,3

ternational application No.

\_\_\_\_\_

PCT/EP 99/06682

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.:  10 because they relate to subject matter not required to be searched by this Authority, namely:  Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery.
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

Information on patent family members

Inte onal Application No
PCT/EP 99/06682

Patent document cited in search repor	t	Publication date	ļ	Patent family member(s)	Publication date
WO 9210218	Α	25-06-1992	CA	2094908 A	07-06-1992
			DE	69121587 D	26-09-1996
			DE	69121587 T	27-03-1997
			EP	0560934 A	22-09-1993
			JP	6506366 T	21-07-1994
WO 9807384	 А	26-02-1998	US	5919234 A	06-07-1999
			AU	3907197 A	06-03-1998
			EP	0928168 A	14-07-1999
US 4186448	A	05-02-1980	 JР	1673618 C	26-06-1992
			JP	3029414 B	24-04-1991
			JP	56080241 A	01-07-1981
WO 9528900	 А	02-11-1995	DE	4414675 C	28-09-1995
			AT	17 <b>95</b> 86 T	15-05-1999
			AU	1665495 A	16-11-1995
			BR	9507856 A	09-06-1998
			CN	1149247 A	07-05-1997
			DE	59505849 D	10-06-1999
			EP	0758872 A	26-02-1997
			ES	2131306 T	16-07-1999
			JP	9512185 T	09-12-1997
			US 	5824088 A	20-10-1998
US 5380328	Α	10-01-1995	NONE		